Trial site

Yuebei People's Hospital

Shaoguan, 512000, ChinaNot linked to an institution yet

15running trials
4closed trials

The trials here

What the 19 trials at this site are about, from their registry records.

Conditions: Stroke5 trials
Lung cancer3 trials
Chronic kidney disease2 trials
Gastric and oesophageal cancer2 trials
Liver and biliary tract cancer2 trials
ANCA-associated vasculitis1 trial
Atopic dermatitis (eczema)1 trial
Crohn's disease1 trial
Ovarian cancer1 trial
Triple-negative breast cancer1 trial
Phase: Phase 311 trials
Phase 22 trials
Phase 42 trials
Phase 2/31 trial
Status: Active, not recruiting6 trials
Not yet recruiting6 trials
Completed4 trials
Recruiting3 trials
Lead sponsor: Guangdong Provincial People's Hospital2 trials
Shanghai Junshi Bioscience Co., Ltd.2 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 trials
Beijing InnoCare Pharma Tech Co., Ltd.1 trial
Biotheus Inc.1 trial
and 11 more

Running trials

Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Not yet recruiting
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source
Contact: zhengyu song
Not yet recruiting
Butylphthalide for Brain Edema After Endovascular Treatment
NCT07528456· Phase 4· Nanfang Hospital, Southern Medical University· Source
Contact: Junbin Chen
Recruiting
A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well
NCT07361302· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
NCT07366528· Phase 3· Ruijin Hospital· Source
Contact: Guoxiong Zhang
Recruiting
BDB-001 Phase III Trial in ANCA-Associated Vasculitis
NCT07168161· Phase 3· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Contact: Hai Wang
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792· Guangdong Provincial People's Hospital· Source
Contact: Min He
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Weiquan Li
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
NCT06419621· Phase 3· Biotheus Inc.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
NCT06984588· Phase 2/3· TJ Biopharma Co., Ltd.· Source
Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
NCT06157060· Zhujiang Hospital· Source
Contact: Qingsong Wu, Prof.
Active, not recruiting
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Active, not recruiting
ASPIrin in Reducing Events in Dialysis ( ASPIRED )
NCT04381143· Phase 4· Guangdong Provincial People's Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Stroke2 recruiting
ANCA-associated vasculitis1 recruiting
Atopic dermatitis (eczema)1 recruiting
Chronic kidney disease1 recruiting
Crohn's disease1 recruiting
Gastric and oesophageal cancer1 recruiting
Liver and biliary tract cancer1 recruiting
Ovarian cancer1 recruiting

Closed trials

Completed
Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke
NCT06202378· Phase 2· Shanghai Hutchison Pharmaceuticals Limited· Source
Completed
Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke
NCT05631847· Sichuan Academy of Medical Sciences· Source
Completed
rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)
NCT05700591· Phase 3· Tasly Biopharmaceuticals Co., Ltd.· Source
Completed
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
NCT04723004· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

Site data: ClinicalTrials.govUpdated 12 Nov 2026

Report an error